CAPE TOWN, South Africa and SAN DIEGO, Calif., October 6th, 2026 — xTenure and SeekIn today announced the signing of a strategic agreement to make SeekIn’s OncoSeek™ multi-cancer early detection (MCED) blood test available in South Africa, with plans to expand access across the broader Southern Africa region.
The collaboration brings together SeekIn’s innovative, low-cost MCED technology with xTenure’s advanced artificial intelligence platform to improve early cancer detection at scale. Designed for emerging markets, the OncoSeek test enables non-invasive detection of multiple cancers from a single blood sample, helping address critical gaps in early diagnosis and screening infrastructure.
Under the agreement, xTenure will lead regional implementation, commercialization, and operations, leveraging its AI-driven platform to guide patient selection and optimize screening intervals. This data-driven approach is expected to significantly enhance the clinical utility and cost-effectiveness of MCED testing for healthcare systems and insurers.
“Early cancer detection remains one of the most powerful levers we have to reduce mortality and healthcare costs globally, yet access remains highly uneven,” said Pieter van Rooyen, co-founder and chairman of xTenure. “By combining SeekIn’s highly scalable and affordable MCED technology with our AI platform, we can intelligently identify who should be screened and how often - dramatically improving outcomes while reducing unnecessary spend. This partnership represents a major step toward equitable cancer screening across Southern Africa.”
OncoSeek uses a panel of protein biomarkers combined with AI algorithms to assess cancer risk and predict potential tissue of origin. The test is designed for integration into standard clinical laboratory workflows, making it particularly suitable for regions with limited access to advanced diagnostic infrastructure.
“We are excited to partner with xTenure to expand access to early cancer detection in South Africa and beyond,” said Mao Mao, founder and CEO of SeekIn. “Our mission is to make accurate, affordable cancer screening available to populations worldwide. xTenure’s strong regional expertise and AI capabilities make them an ideal partner to bring OncoSeek to emerging markets where the need is greatest.”
The companies will initially focus on South Africa, with a roadmap to extend availability to additional countries across Southern Africa, including key healthcare markets in the region. The partnership also includes plans for clinical validation, regulatory engagement, and localized deployment strategies to ensure successful adoption.
SeekIn has rapidly expanded the global footprint of its MCED technologies, with OncoSeek currently deployed in multiple countries across Asia, Europe, Africa, and North and South America. The company continues to advance large-scale clinical validation efforts to support broader adoption of blood-based multi-cancer screening.
xTenure’s AI platform plays a central role in the partnership by enabling precision population health strategies. By integrating clinical, demographic, and risk data, the platform helps healthcare providers and payers identify high-risk individuals, optimize screening cadence, and improve overall program efficiency.
Together, the companies aim to redefine cancer screening paradigms in resource-constrained settings, delivering scalable, data-driven solutions that improve early detection rates while reducing systemic costs.
About xTenure
xTenure is an advanced artificial intelligence platform company focused on transforming healthcare delivery through predictive analytics and precision population health. Its technology enables smarter screening, risk stratification, and clinical decision support to improve outcomes and reduce costs across global healthcare systems. xTenure's comprehensive, trajectory-based latent disease AI platform provides a funnel-based, low-cost pre-screening for cancer to make global-scale early cancer screening using MCED economically viable and medically impactful
About SeekIn
SeekIn Inc. is a biotechnology company specializing in blood-based pan-cancer early detection powered by multi-omics technologies, big data, and artificial intelligence. Since its inception, SeekIn has been dedicated to delivering cutting-edge, cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. The company has also developed novel molecular tests for patients with leukemia, and its cancer early detection technology has been successfully applied in canines. Building on its proprietary technical advances, SeekIn has launched multiple research and clinical studies in collaboration with top-tier hospitals worldwide. SeekIn envisions that, by establishing a new norm for cancer early detection, clinical outcomes for patients with mid- and late-stage cancers can be improved and cancer-related mortality reduced by 15%. For more information about SeekIn’s technologies and products, visit www.seekincancer.com.
Media Contacts:
xTenure: info@xtenure.com
SeekIn: info@seekincancer.com